Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a Synapse-Targeting drug slow Alzheimer's?

NCT ID NCT05531656

Disease control Sponsor: Cognition Therapeutics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 2 times

Summary

This Phase 2 trial tests an experimental drug called CT1812 in 540 people with early Alzheimer's disease. Participants receive either the drug or a placebo for 18 months. The goal is to see if CT1812 can slow declines in memory, thinking, and daily function. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CT1812 (a drug that targets synaptic receptors to protect brain cells)
What this could lead to
If successful, this could lead to a new treatment that slows memory loss and functional decline in early Alzheimer's disease.
What could go wrong
This is a mid-stage trial; results may not confirm benefit. The drug could cause side effects or fail to slow cognitive decline compared to placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 540 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ages 50-85 years. 2. Diagnosis of either MCI due to AD or mild AD dementia. 3. MMSE 20-30 (inclusive). 4. Amyloid PET scan of the brain or CSF biomarkers consistent with AD. 5. Neuroimaging (MRI) obtained during screening consistent with the clinical diagnosis of Alzheimer's disease, as based on central read. Exclusion Criteria: 1. Screening MRI of the brain indicative of significant abnormality. 2. Clinically significant abnormalities in screening laboratory tests. 3. Clinical or laboratory findings consistent with: 1. Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Creutzfeldt-Jakob Disease, Down syndrome, etc.). 2. Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.). 3. Other infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, present hypothyroidism, present vitamin B12, other laboratory values etc.) 4. A participant known to be actively infected with hepatitis B or hepatitis C at screening. History of acute/chronic hepatitis B or C and/or carriers of hepatitis B (seropositive for hepatitis B surface antigen \[HbsAg\] or anti-hepatitis C \[HCV\] antibody). Participants who have evidence of resolved hepatitis infection (e.g., HCV RNA negative) may be considered following discussion with the Medical Monitor. 5. A current DSM-V diagnosis of active major depression or GDS \> 6, schizophrenia, or bipolar disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Early Alzheimer's disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Early Alzheimer's disease

Contacts and locations

Locations

  • Abington Neurological Associates

    Abington, Pennsylvania, 19001, United States

  • Advanced Clinical Research Network, Corp

    Miami, Florida, 33135, United States

  • Banner Alzheimer's Institute

    Phoenix, Arizona, 85006, United States

  • Banner Sun Health Research Institute

    Sun City, Arizona, 85351, United States

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Brain Matters Research

    Delray Beach, Florida, 33445, United States

  • Brain Matters Research Stuart

    Stuart, Florida, 34997, United States

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Butler Hospital

    Providence, Rhode Island, 02906, United States

  • Case Western Reserve University / University Hospitals

    Beachwood, Ohio, 44122, United States

  • Central States Research, LLC

    Tulsa, Oklahoma, 74136, United States

  • Charter Research

    Orlando, Florida, 32803, United States

  • Cleveland Clinic Lou Ruvo Center for Brain Health

    Las Vegas, Nevada, 89106, United States

  • Columbia University Medical Center

    New York, New York, 10032, United States

  • Conquest Research, LLC

    Winter Park, Florida, 32789, United States

  • Georgetown University

    Washington D.C., District of Columbia, 20057, United States

  • Headlands Research Orlando

    Orlando, Florida, 32819, United States

  • Highlands Research Eastern MA

    Plymouth, Massachusetts, 02360, United States

  • Houston Methodist Neurological Institute

    Houston, Texas, 77030, United States

  • Howard University

    Washington D.C., District of Columbia, 20060, United States

  • Indiana University

    Indianapolis, Indiana, 46202, United States

  • JEM Research Institute

    Lake Worth, Florida, 33462, United States

  • John Hopkins University

    Baltimore, Maryland, 21224, United States

  • K2 Medical Research, LLC

    Maitland, Florida, 32751, United States

  • Mayo Clinic, Rochester

    Rochester, Minnesota, 55901, United States

  • Mayo Clinic,Jacksonville

    Jacksonville, Florida, 32216, United States

  • Mount Sinai School of Medicine

    New York, New York, 10029, United States

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida, 33912, United States

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • Ralph H. Johnson VA MC

    Charleston, South Carolina, 29401, United States

  • Rush University Medical Center

    Chicago, Illinois, 60612, United States

  • Sanders-Brown Center on Aging

    Lexington, Kentucky, 40504, United States

  • Stanford University

    Palo Alto, California, 94304, United States

  • Summit Headlands LLC

    Portland, Oregon, 97210, United States

  • Sutter Institute for Medical Research

    Sacramento, California, 95816, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

  • University of California

    Irvine, California, 92697, United States

  • University of Michigan, Ann Arbor

    Ann Arbor, Michigan, 48109, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Rochester Medical Center

    Rochester, New York, 14620, United States

  • University of South Florida

    Tampa, Florida, 33613, United States

  • University of Texas Health Science Center

    San Antonio, Texas, 78229, United States

  • University of Texas Southwestern Medical Center

    Dallas, Texas, 75390, United States

  • University of Wisconsin

    Madison, Wisconsin, 53726, United States

  • Vanderbilt University Medical Center Center for Cognitive Medicine

    Nashville, Tennessee, 37212, United States

  • Vanderbilt University Medical Center Center for Cognitive Medicine

    Nashville, Tennessee, 37232, United States

  • Wake Forest University Health Sciences

    Winston-Salem, North Carolina, 27157, United States

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

  • Yale University

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.